Institutional members access full text with Ovid®

Share this article on:

SHORT-TERM EFFICACY OF CONBERCEPT AND RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY

Huang, Zhen, MD; Ding, Qin, MBBS; Yan, Min, MD; Lian, Haiyan, MD; Chen, Zhongshan, MD; Chen, Xiao, MD; Song, Yanping, MD

doi: 10.1097/IAE.0000000000002035
Original Study: PDF Only

Purpose: To compare the 6-month efficacy of the intravitreal injection of conbercept or ranibizumab for patients with polypoidal choroidal vasculopathy (PCV).

Methods: This is a retrospective case–control study involved 79 PCV eyes of 77 patients. The PCV eyes were treated with an intravitreal injection of either ranibizumab (n = 44) or conbercept (n = 35). Three monthly loading doses were injected and followed by retreatment as needed. The best-corrected visual acuity and angiographic characteristics were evaluated after 6 months.

Results: The mean logarithm of the minimum angle of resolution best-corrected visual acuity had improved from 0.86 (Snellen equivalent, 20/145) at baseline to 0.70 (Snellen equivalent, 20/100) at 6 months in the conbercept group (P < 0.001), and from 0.74 (Snellen equivalent, 20/110) at baseline to 0.63 (Snellen equivalent, 20/85) at 6 months in the ranibizumab group (P = 0.032), respectively. The central foveal thickness was decreased from 407 ± 146 μm to 230 ± 71 μm in the conbercept group (P < 0.001), and from 394 ± 93 μm to 208 ± 56 μm in the ranibizumab group (P < 0.001). Polyps were completely regressed and in 21 (47.7%) eyes in the conbercept group at 6 months, significant higher than in 10 (28.6%) eyes in the ranibizumab group (P = 0.029).

Conclusion: Both conbercept and ranibizumab effectively increased the visual acuity and regressed the polyps of PCV eyes. No significant difference was found in the visual acuity improvement of the patients with PCV between the conbercept group and ranibizumab group at 6 months. However, conbercept was superior to ranibizumab monotherapy in the regression of polyps.

In this retrospective case–control study, we compared the 6-month efficacy of conbercept or ranibizumab for patients with polypoidal choroidal vasculopathy. We found that although both conbercept and ranibizumab were able to effectively increase patient's vision acuity; however, conbercept was superior to ranibizumab monotherapy in the regression of polyps.

Department of Ophthalmology, Wuhan General Hospital of People's Liberation Army, Wuhan, China.

Reprint requests: Yanping Song, MD, Department of Ophthalmology, Wuhan General Hospital of People's Liberation Army, No. 627, Wuluo Road, 430070 Wuhan, China; e-mail: songyanping@medmail.com.cn

None of the authors has any financial/conflicting interests to disclose.

© 2018 by Ophthalmic Communications Society, Inc.